Pseudomyxoma peritonei surgery

Jump to navigation Jump to search

Pseudomyxoma peritonei Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Pseudomyxoma peritonei from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pseudomyxoma peritonei surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pseudomyxoma peritonei surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pseudomyxoma peritonei surgery

CDC on Pseudomyxoma peritonei surgery

Pseudomyxoma peritonei surgery in the news

Blogs on Pseudomyxoma peritonei surgery

Directions to Hospitals Treating Pseudomyxoma peritonei

Risk calculators and risk factors for Pseudomyxoma peritonei surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]Parminder Dhingra, M.D. [3]

Overview

Pseudomyxoma peritonei is a rare clinical syndrome characterized by the accumulation of ascites and mucins in the peritoneum, mainly arising from the appendix. The mainstay of therapy in patients with pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemotherapeutic infusion.

Surgery

  • Surgery is the mainstay of treatment for pseudomyxoma peritonei. The traditional approach was repeated surgical debulking, feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis.[1]
  • A more aggressive approach is called cytoreductive surgery (CRS), in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) which has following advantage:
    • Targeting of the microscopic disease
    • Minimal systemic exposure and less toxicity
    • Improved chemotherapeutic drug penetration by warming to 42 degree centigerade and direct peritoneal infusion.[2][3]

References

  1. Qu ZB, Liu LX (October 2006). "Management of pseudomyxoma peritonei". World J. Gastroenterol. 12 (38): 6124–7. PMC 4088104. PMID 17036382.
  2. Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M (2009). "Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience". In Vivo. 23 (4): 639–44. PMID 19567401.
  3. Kitai T, Kawashima M, Yamanaka K, Ichijima K, Fujii H, Mashima S, Shimahara Y (September 2011). "Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals". Surg. Today. 41 (9): 1219–23. doi:10.1007/s00595-010-4495-6. PMID 21874418.


Template:WikiDoc Sources